
Genuv: multispecific cancer antibodies and neuroprotective small molec... Seoul-based Genuv is developing a competitor to Roche’s anti-PD-1:IL-2 fusion for solid tumors; advancing a MEK inhibitor for neurodegenerationBY DANIELLE GOLOVIN, BIOPHARMA ANALYSTSungho Han, a rare female So... BioCentury 2023.07.29
Genuv Teams With Celltrion to Develop Novel mAb Treatments / Genuv Emb... CAMBRIDGE, MASS. (PRWEB) MARCH 15, 2023 Genuv Inc., a clinical-stage biotechnology company focused on drug discovery, and Celltrion, a leading global biopharmaceutical company, have entered into a partnership to jo... PRWeb 2023.03.15
Publication in Nature Molecular Psychiatry Supports Genuv’s Alternate ... Publication in Nature Molecular Psychiatry Supports Genuv’s Alternate Theory for Treatment of Alzheimer’s Disease Article in peer-reviewed publication provides validation of Genuv’s ... BusinessWire 2022.08.18
Genuv Teams With Nanocarry Therapeutics to Develop Novel anti-PD-1 mAb... Genuv Teams With Nanocarry Therapeutics to Develop Novel anti-PD-1 mAb Treatments That Can Cross the Blood-Brain Barrier SEOUL, South Korea & NESS ZIONA, Israel--(BUSINESS WIRE)--Genuv Inc., a clinical-stage... BioSpace 2022.06.06
Genuv Announces Preclinical Data to be Released at Two Medical Confere... Genuv Announces Preclinical Data to be Released at Two Medical Conferences in June 2022 SEOUL, South Korea--(BUSINESS WIRE)-- Genuv Inc., a clinical-stage biotechnology company focused on innovative drug di... BioSpace 2022.05.24
Why We Need an Alzheimer’s Moonshot in 2022 Why We Need an Alzheimer’s Moonshot in 2022 Genuv calls for an urgent, all-hands-on-deck drug development effort to ameliorate the fast-worsening health crisis that is Alzheimer’s disease By Sungho Han, PhD... GEN(Genetic Engineering & Biotechnology News) 2022.05.01
Next-gen IL-2 GNUV204, selected by the Korean government for a develop... Best-in-Class IL2 GNUV204 has been selected by the Korean government for a development grant The Korea Drug Development Fund (KDDF) is contributing more than $750,000 towards the clinical development of GNUV204,... Medigate 2021.12.10
Genuv’s Sungho Han Encourages Her Staff to Challenge the Status Quo Genuv’s Sungho Han Encourages Her Staff to Challenge the Status Quo Genuv’s CEO Sungho Han, Ph.D., is a true Renaissance woman: a scientist, entrepreneur, patent law expert, conservatory-trained orga... BioSpace 2021.11.10